NasdaqCM:VSTMBiotechs
Verastem (VSTM): Persistent Losses Challenge Bullish Growth Narrative Despite 55.7% Revenue Forecast
Verastem (VSTM) is on track for standout top-line growth, with revenue forecast to surge 55.7% per year, well ahead of the broader US market’s 10.5% pace. Despite this bullish revenue outlook, the company remains unprofitable and is projected to stay in the red for at least the next three years, as losses have risen by 23.7% per year over the past five years without net margin improvement. Investor focus this quarter will be on whether Verastem can turn strong growth potential into a path...